Momelotinib filed in Japan to treatmyelofibrosis
GlaxoSmithKline has filed a new drug application in Japan for the investigational myelofibrosis treatment momelotinib, a compound acquired through its buyout of Sierra Oncology in July last year
Momelotinib has a unique mechanism of action designed to inhibit three key signaling pathways, JAK1, JAK2, and activin A receptor, type I (ACVR1). The drug has not been approved in any market.
In the US, Sierra had filed the drug in June 2022 prior to the acquisition, while in Europe, GSK had announced its regulatory submission in December that year.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.